The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Real-world impact of adjuvant chemotherapy on patients with pT4N0 colon cancer
Alberto Puccini, MD, IRCCS Humanitas Research Hospital, Milan, Italy, discusses findings from a multicenter, real-world analysis of patients with stage II (pT4N0) colon, focusing on the impact of DNA mismatch repair (dMMR) status and type of adjuvant chemotherapy on outcomes. The results demonstrated that adjuvant chemotherapy, especially oxaliplatin-based regimens, significantly improved relapse-free survival (RFS) and overall survival (OS). Six-month adjuvant chemotherapy additionally showed a trend towards better outcomes compared to three-month regimens. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
